Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

RELiZORB®

To Patients

To Patients

Therapeutic Approach

Nutritional-GI

RELiZORB® is a digestive enzyme cartridge that connects to enteral tube feeding systems. It is designed to mimic normal pancreatic function by helping to break down the fats in enteral tube feeding formula. By breaking down these fats before the formula is ingested, RELiZORB® may allow for delivery of increased absorbable calories and simplify the use of enzymes in overnight feedings. 

Status

RELiZORB® is FDA-approved for people who are partially or completely unable to break down and absorb fats. Two studies to test the safety, tolerability and effectiveness of RELiZORB® in people with CF have been completed.

Sponsor

This program was sponsored by Alcresta and partially funded by the Cystic Fibrosis Foundation. It was conducted within the Therapeutics Development Network.



Contact us about RELiZORB® >